Global Community

Acquisition of V TEX Corporation A franchise-defining semiconductor acquisition – With the ¥9.4bn acquisition of VTEX, KITZ becomes the clear global number two in semiconductor vacuum valves, with ~9% market share and the leading supplier within the booming Japanese Wafer Fab Equipment (WFE) supply chain. While the market may view this as a minor bolt-on acquisition, we believe it is a franchise-defining transaction of significant strategic importance.Read more

Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer.Read more

Novo Nordisk occupies an enviable position as a dominant player in a strict global duopoly (alongside Eli Lilly) disrupting the cardiometabolic healthcare landscape. Driven by its blockbuster semaglutide platform (Ozempic, Wegovy, Rybelsus), the company has transformed from a mature legacy insulin provider into a high-growth compounding machine.Read more

Nova Ljubljanska Banka is betting it can keep earnings strong while returning more cash to shareholders, helped by better efficiency and new sources of income. The big question is whether it can hold up its lending profits and expand into nearby markets without running into political and competitive headaches.Read more

Investment Thesis Palantir is positioning itself as a foundational AI deployment layer for governments and regulated industries. Unlike model providers or infrastructure hyperscalers, Palantir integrates AI into live operational workflows, with security controls, compliance guardrails, and auditability embedded into the platform.Read more

Cboe runs the behind-the-scenes markets where many investors and companies trade options, currency products, and market data, and its latest results point to growing demand across several parts of the business. The company looks like it can keep expanding profits while benefiting from hard-to-copy advantages like regulation and scale, but the big question is whether that strong momentum can last.Read more

Why the Market is Wrong About the ARS Pharma vs. Aquestive "Duopoly" Ticker: ARS Pharmaceuticals, Inc.Read more

Lion One Metals’ outlook changes dramatically if gold prices jump, turning its planned production into a much bigger cash generator. See how higher output and steady costs could reshape what the business might be worth—and what could derail that story.Read more

Investment Thesis : Renforth Resources represents a highly asymmetric structural M&A play in the infrastructure-dense Abitibi Greenstone Belt. The core narrative relies on a critical operational bottleneck faced by regional major Agnico Eagle, juxtaposed against Renforth’s aggressive independent path to near-term monetization.Read more